StockWatch
·
Misc Health and Biotechnology Services
Quarterly ResultAug 4, 2026, 05:08 PM

DaVita Q2 Diluted EPS $4.02, Net Income $265.4M

AI Summary

DaVita Inc. reported strong financial results for the second quarter and first six months of 2026. Diluted earnings per share for Q2 2026 increased to $4.02, up from $2.58 in the prior year, with net income attributable to DaVita Inc. rising to $265.4 million. Total revenues for the quarter reached $3.55 billion. For the six months ended June 30, 2026, diluted EPS was $6.86 on net income of $462.9 million and total revenues of $6.97 billion. The company also amended its Credit Agreement, extending $500 million on its Term Loan B-2, and continues to cooperate with several ongoing governmental investigations.

Key Highlights

  • Q2 2026 diluted EPS increased to $4.02 from $2.58 in Q2 2025.
  • Q2 2026 net income attributable to DaVita Inc. rose to $265.4M from $199.3M.
  • Q2 2026 total revenues increased to $3.55B from $3.38B in Q2 2025.
  • Six-month 2026 diluted EPS increased to $6.86 from $4.57 in six-month 2025.
  • Six-month 2026 net income attributable to DaVita Inc. rose to $462.9M from $362.3M.
  • Six-month 2026 total revenues increased to $6.97B from $6.60B in six-month 2025.
  • Company entered Ninth Amendment to Credit Agreement, extending $500M on Term Loan B-2.
  • Ongoing legal proceedings include investigations by US Attorney, CDI, DC Attorney General, and FTC.